Site for S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Brief description of study
Site for This is a randomized Phase III trial. Eligible participants either are known to have ultrahigh risk (MP2) status using MammaPrint or will undergo screening to determine eligibility. Patients will be initially enrolled in Step 1 to determine eligibility. Participants who do not have MP2 at that time will not be followed further. Participants with MP2 status who consent to be randomized will be enrolled in this parallel randomization open-label design with equal allocation to the two treatment groups: (1) neoadjuvant chemotherapy and (2) neoadjuvant chemotherapy concurrent with durvalumab.
Clinical Study Identifier: s23-01466
ClinicalTrials.gov Identifier: NCT06058377
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
